Bladder cancer: II. Molecular aspects and diagnosis

European Urology

Volumn 39, Issue 5, 2001, Pages 498-506

  Kausch, I ^a   Bohle A ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Biological markers; Bladder cancer; Indicators; Molecular markers; Review; Tumor markers; Urinalysis

Indexed keywords

TUMOR MARKER;

BLADDER CANCER; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CYSTOSCOPY; DIAGNOSTIC PROCEDURE; FOLLOW UP; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY;

ANTIGENS, NEOPLASM; CYSTOSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; IMMUNOASSAY; KERATINS; NUCLEAR PROTEINS; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS; URINE;

EID: 0034917708     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052495     Document Type: Review

References (78)

1. Prognostic markers in bladder cancer: A contemporary review of the literature
2. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome
3. Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests?
4. Cell surface differentiation antigens of normal urothelium and bladder tumors
5. Critical appraisal of tumor markers in bladder cancer
6. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells
7. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group
8. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring
9. Monoclonal antibody 486 P 3/12: A valuable bladder carcinoma marker for immunocytology
10. Identification by monoclonal antibodies of an antigen shed by human bladder cancer cells
11. Bladder squamous cell carcinomas express psoriasin and externalise it to the urine
12. Improved detection of recurrent bladder cancer using the Bard BTA stat test
13. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer
14. Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients
15. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer
16. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms
17. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group
18. Noninvasive detection of bladder cancer with the BTA STAT test
19. Comparison of screening methods in the detection of bladder cancer
20. Wertigkeit von BTA-test und urinzytologie bei der diagnostik und nachsorge des harnblasenkarzinoms
21. BTA-TRAK - A useful diagnostic tool in urinary bladder cancer?
22. BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder
23. Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract
24. Use of urine-based markers for detection and monitoring of bladder cancer
25. Bladder cancer-associated nuclear matrix proteins
26. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
27. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
28. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
29. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer
30. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer
31. TM-test replace cystoscopy?
32. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat
33. Urine cytology, tumour markers and bladder cancer
34. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation
35. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder
36. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine
37. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors
38. Evaluation of biological markers in bladder cancer
39. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer
40. Rapid detection of bladder cancer: A comparative study of point of care tests
41. Telomerase activity in human urothelial tumors
42. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer
43. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine
44. Urothelial differentiation and bladder cancer
45. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis
46. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials
47. Gelsolin: A candidate for suppressor of human bladder cancer
48. Cytokeratin expression patterns in normal and malignant urothelium: A review of the biological and diagnostic implications
49. Cytokeratins in normal and malignant transitional epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines
50. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies
51. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer
52. Serum tissue polypeptide antigen in bladder cancer as a tumor marker: A prospective study
53. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma
54. Initial evaluation of CYFRA 21-1 diagnostic performances and a urinary marker in bladder transitional cell carcinoma
55. Molecular detection of primary bladder cancer by microsatellite analysis
56. Four tumor suppressor loci on chromosome 9q in bladder cancer: Evidence for two novel candidate regions at 9q22.3 and 9q31
57. Microsatellite alterations in superficial and locally advanced transitional cell carcinoma of the bladder
58. Detection of bladder cancer recurrence by microsatellite analysis of urine
59. Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients
60. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder
61. The asymmetric unit membranes of the epithelium of the urinary bladder of the rat. An electron microscopic study of a mechanism of epithelial maturation and function
62. Large scale purification and immunolocalization of bovine uroplakins I, II and III. Molecular markers of urothelial differentiation
63. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas
64. Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8-10/CD44v10 competitive RT-PCR
65. Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer
66. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells
67. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia
68. Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer
69. Tumor-derived hyaluronidase: A diagnostic urine marker for high-grade bladder cancer
70. Bladder wash cytology, quantitative cytology and the quantitative BTA test in patients with superficial bladder cancer
71. Usefulness of the BTA test in the detection of bladder cancer
72. Multi-center trial of the quantitative BTA TRAK assay in the detection of bladder cancer
73. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer
74. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer
75. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: Analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer